Drug intelligence / Profile preview

GSK2592984A

Development stage: Phase 1
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**GSK2592984A** is GSK's investigational, cell-culture-derived, unadjuvanted split-virus pandemic influenza vaccine based on the *Influenza A* A/Indonesia/5/2005 H5N1 strain. It was evaluated as a two-dose candidate vaccine in a completed Phase 1 study in healthy adults aged 18–49 years, designed to assess safety and immunogenicity. The product is distinct from the related adjuvanted GSK2590066A candidate and has no identified INN or marketed brand name. ([s3.amazonaws.com](https://s3.amazonaws.com/ctr-gsk-7381/114371/69cc5cb4-837b-465c-8f08-8e11d722be50/750bdf60-f4d9-4bb9-95ef-43946506d404/17055549-feed-4c7f-aa03-ceca745783ba-v1.pdf))

Brand names: Pandemrix
Other names: CC-PAN-2CC-PAN2CC-PAN 2

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on GSK2592984A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2592984A.

Explore the full profile